JP2013523898A - ポリ−ｎ−アセチルグルコサミンナノファイバーの抗菌性の適用 - Google Patents

ポリ−ｎ−アセチルグルコサミンナノファイバーの抗菌性の適用 Download PDF

Info

Publication number
JP2013523898A
JP2013523898A JP2013505181A JP2013505181A JP2013523898A JP 2013523898 A JP2013523898 A JP 2013523898A JP 2013505181 A JP2013505181 A JP 2013505181A JP 2013505181 A JP2013505181 A JP 2013505181A JP 2013523898 A JP2013523898 A JP 2013523898A
Authority
JP
Japan
Prior art keywords
snag
infection
bacterial
wound
snag nanofibers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2013505181A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013523898A5 (OSRAM
Inventor
ヴォルナキス，ジョーン，エヌ．
フィンキールシュタイン，セルジオ
Original Assignee
マリン ポリマー テクノロジーズ，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by マリン ポリマー テクノロジーズ，インコーポレーテッド filed Critical マリン ポリマー テクノロジーズ，インコーポレーテッド
Publication of JP2013523898A publication Critical patent/JP2013523898A/ja
Publication of JP2013523898A5 publication Critical patent/JP2013523898A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2013505181A 2010-04-15 2011-04-15 ポリ−ｎ−アセチルグルコサミンナノファイバーの抗菌性の適用 Withdrawn JP2013523898A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32465710P 2010-04-15 2010-04-15
US61/324,657 2010-04-15
PCT/US2011/032709 WO2011130646A1 (en) 2010-04-15 2011-04-15 Anti-bacterial applications of poly -n-acetylglucosamine nanofibers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016095328A Division JP6400628B2 (ja) 2010-04-15 2016-05-11 ポリ−ｎ−アセチルグルコサミンナノファイバーの抗菌性の適用

Publications (2)

Publication Number Publication Date
JP2013523898A true JP2013523898A (ja) 2013-06-17
JP2013523898A5 JP2013523898A5 (OSRAM) 2014-06-05

Family

ID=44799052

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2013505181A Withdrawn JP2013523898A (ja) 2010-04-15 2011-04-15 ポリ−ｎ−アセチルグルコサミンナノファイバーの抗菌性の適用
JP2016095328A Active JP6400628B2 (ja) 2010-04-15 2016-05-11 ポリ−ｎ−アセチルグルコサミンナノファイバーの抗菌性の適用
JP2018166053A Expired - Fee Related JP6761453B2 (ja) 2010-04-15 2018-09-05 ポリ−ｎ−アセチルグルコサミンナノファイバーの抗菌性の適用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2016095328A Active JP6400628B2 (ja) 2010-04-15 2016-05-11 ポリ−ｎ−アセチルグルコサミンナノファイバーの抗菌性の適用
JP2018166053A Expired - Fee Related JP6761453B2 (ja) 2010-04-15 2018-09-05 ポリ−ｎ−アセチルグルコサミンナノファイバーの抗菌性の適用

Country Status (12)

Country Link
US (5) US8858964B2 (OSRAM)
EP (1) EP2563371A4 (OSRAM)
JP (3) JP2013523898A (OSRAM)
KR (1) KR101883797B1 (OSRAM)
CN (2) CN107412772A (OSRAM)
AU (1) AU2011239466B2 (OSRAM)
BR (1) BR112012025844A2 (OSRAM)
CA (1) CA2796068C (OSRAM)
IL (1) IL222375A (OSRAM)
MX (1) MX342912B (OSRAM)
NZ (2) NZ703163A (OSRAM)
WO (1) WO2011130646A1 (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015048436A (ja) * 2013-09-03 2015-03-16 公立大学法人福井県立大学 植物の耐病性を向上させる、生物由来キチン質含有物、その使用方法、及びその製造方法

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3000487B8 (en) 2007-02-19 2022-06-15 Marine Polymer Technologies, Inc. Hemostatic compositions and therapeutic regimens
CN107412772A (zh) 2010-04-15 2017-12-01 海洋聚合物技术公司 聚‑n‑乙酰葡萄糖胺纳米纤维的抗菌应用
CA2832859C (en) 2011-04-15 2020-06-16 Marine Polymer Technologies, Inc. Treatment of disease with poly-n-acetylglucosamine nanofibers
CA2850366A1 (en) * 2011-09-30 2013-04-04 The Research Institute At Nationwide Children's Hospital Compositions and methods for detection of defensins in a patient sample
US10124051B2 (en) * 2012-05-22 2018-11-13 Glaxosmithkline Biologicals Sa Meningococcus serogroup X conjugate
US20150237837A1 (en) * 2012-06-18 2015-08-27 Duke University Non-Human Model for Wound Healing
WO2014098865A1 (en) 2012-12-20 2014-06-26 Hill's Pet Nutrition, Inc. Pattern recognition receptor expression as a measure of systemic health
EP2968190B1 (en) 2013-03-14 2018-10-17 Marine Polymer Technologies, Inc. Treatment of disease with poly-n-acetylglucosamine nanofibers
EP3034612A1 (en) 2014-12-16 2016-06-22 Greenaltech, S.L. Chitin and chitosan producing methods
US10500222B2 (en) * 2015-10-19 2019-12-10 Wayne State University Compositions and methods relating to treatment of infection
CN107460140B (zh) * 2016-06-02 2020-11-13 浙江科技学院 一种芽孢杆菌hz16中抑制军团菌活性物的制备方法
WO2019046577A1 (en) 2017-08-31 2019-03-07 Syngulon Sa METHODS AND COMPOSITIONS FOR THE PRODUCTION OF BACTERIOCIN AND ANTIMICROBIAL PEPTIDES
US20210169922A1 (en) * 2018-05-11 2021-06-10 Marine Polymer Technologies, Inc. Use of poly-n-acetylglucosamine nanofibers for the treatment of gingival recession
BR102021021376A2 (pt) * 2021-10-25 2023-05-09 União Brasileira De Educação Católica - Ubec Composição, processo de produção da composição e uso da composição de nanofibras que compreende pva, quitosana, antibiótico e peptídeo de defesa do hospedeiro
IT202200004574A1 (it) 2022-03-10 2023-09-10 Sergio Ammendola Nanoparticelle di N-acetilglucosammina e loro applicazioni
KR102846669B1 (ko) * 2022-04-14 2025-08-13 충남대학교산학협력단 miRNA 24가 봉입된 키토산 나노입자를 유효성분으로 포함하는 에드워드시엘라 피스시시다에 대한 어류용 항생 조성물
CN115671368B (zh) * 2022-10-28 2024-03-22 东华大学 一种用于生物膜清除的纳米纤维复合贴片及其制备方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09506126A (ja) * 1993-12-01 1997-06-17 マリン ポリマー テクノロジーズ，インコーポレーテッド ポリ−β−１→４−Ｎ−アセチルグルコサミン
JP2003160602A (ja) * 2001-11-28 2003-06-03 Japan Atom Energy Res Inst 橋かけ構造を有するキチン誘導体及び／又はキトサン誘導体の製造方法
JP2006518764A (ja) * 2003-02-24 2006-08-17 マリン ポリマー テクノロジーズ，インコーポレーテッド 細胞−ポリマー繊維組成物及びその使用
JP2008019264A (ja) * 2002-08-02 2008-01-31 Engelhard Lyon ２型又は３型ヒトβ−デフェンシンを刺激する活性成分とその活性成分を含有する化粧用組成物及び医薬組成物
WO2008103345A2 (en) * 2007-02-19 2008-08-28 Marine Polymer Technologies, Inc. Hemostatic compositions and therapeutic regimens
WO2009095456A1 (en) * 2008-01-30 2009-08-06 Diverdrugs S.L. Peptide derivatives useful in the treatment, care or cleansing of the skin, mucosae, scalp or nails

Family Cites Families (141)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1038367A (en) 1963-05-28 1966-08-10 Beecham Group Ltd Penicillin derivatives
US3988411A (en) 1974-02-11 1976-10-26 American Cyanamid Company Spinning and shaping poly-(N-acetyl-D-glucosamine)
US3989535A (en) 1974-02-11 1976-11-02 American Cyanamid Company Solution of poly(N-acetyl-D-glucosamine)
US4068757A (en) 1976-11-03 1978-01-17 American Cyanamid Company Chitin derived powder in sterile surgical element package
US4195175A (en) 1978-01-03 1980-03-25 Johnson Edwin L Process for the manufacture of chitosan
JPS55152705A (en) 1979-05-18 1980-11-28 Mitsubishi Rayon Co Ltd Preparation of water-soluble alkali chitin
JPS56131639A (en) 1980-03-21 1981-10-15 Kureha Chem Ind Co Ltd Protein-chitosan composition
JPS56133344A (en) 1980-03-21 1981-10-19 Kureha Chem Ind Co Ltd Novel composite material
US4378017A (en) 1980-03-21 1983-03-29 Kureha Kagaku Kogyo Kabushiki Kaisha Composite material of de-N-acetylated chitin and fibrous collagen
US4532134A (en) 1981-04-06 1985-07-30 Malette William Graham Method of achieving hemostasis, inhibiting fibroplasia, and promoting tissue regeneration in a tissue wound
US4394373A (en) 1981-04-06 1983-07-19 Malette William Graham Method of achieving hemostasis
US4470397A (en) 1981-11-11 1984-09-11 Lucas Industries Public Limited Company Fuel injection pumping apparatus
US4605623A (en) 1982-11-08 1986-08-12 Malette William Graham Method of altering growth and development and suppressing contamination microorganisms in cell or tissue culture
JPS5998660A (ja) 1982-11-26 1984-06-07 House Food Ind Co Ltd 麺類の乾燥方法
JPS59156770A (ja) 1983-02-25 1984-09-06 Canon Inc インパクト型プリンタ
JPS58220899A (ja) 1983-03-22 1983-12-22 工業技術院長 キチン系抄造体の製造方法
JPS6025003A (ja) 1983-07-20 1985-02-07 Shiro Okamura 光磁気記録装置
US4803168A (en) 1983-09-01 1989-02-07 Damon Biotech, Inc. Microencapsulation with polymers
US4749620A (en) 1984-02-15 1988-06-07 Massachusetts Institute Of Technology Encapsulated active material system
JPS60208302A (ja) 1984-03-31 1985-10-19 Unitika Ltd キチン成形体の製造方法
JPS60215003A (ja) 1984-04-10 1985-10-28 Unitika Ltd キトサン成形体の製造方法
EP0171254B1 (en) 1984-08-03 1991-06-19 Unitika Ltd. Shaped chitin body
JPH0611810B2 (ja) 1984-08-23 1994-02-16 ユニチカ株式会社 多孔性キチン成形体及びその製造方法
JPS61253065A (ja) 1985-05-02 1986-11-10 片倉チツカリン株式会社 キトサン誘導体およびコラ−ゲンの複合材の医用材料およびその製造法
US4895724A (en) 1985-06-07 1990-01-23 Pfizer Inc. Chitosan compositions for controlled and prolonged release of macromolecules
JPS62288602A (ja) 1986-06-06 1987-12-15 Agency Of Ind Science & Technol キトサン変性物粒子の製造方法
ATE144781T1 (de) 1986-06-06 1996-11-15 Union Carbide Corp Saure dekristallisierung von hochkristallin chitosan oder teilentacetylierten chitin
JPH0441422Y2 (OSRAM) 1986-10-17 1992-09-29
JPH0525289Y2 (OSRAM) 1987-01-21 1993-06-25
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4942129A (en) 1987-07-28 1990-07-17 Queen's University At Kingston Multiple membrane microencapsulation
US5571821A (en) 1993-05-20 1996-11-05 Texas Biotechnology Corporation Sulfonamides and derivatives thereof that modulate the activity of endothelin
JPH0532702Y2 (OSRAM) 1987-10-09 1993-08-20
JP2560363B2 (ja) 1987-12-23 1996-12-04 ライオン株式会社 キチン又はキトサン類の精製法
EP0330106A1 (de) 1988-02-25 1989-08-30 Akzo Nobel N.V. Modifizierte Cellulose für biocompatible Dialysemembranen II und Verfahren zu deren Herstellung
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5008116A (en) 1988-11-14 1991-04-16 Frederick Cahn Immunostimulatory microsphere
DE3903797A1 (de) 1989-02-09 1990-08-16 Hoechst Ag Verfahren zur herstellung von aktivierten chitosanen und deren verwendung bei der herstellung von chitosanderivaten
JPH0657761B2 (ja) 1989-02-27 1994-08-03 富士紡績株式会社 多孔質キトサン成形物の製造法
JPH02240101A (ja) 1989-03-14 1990-09-25 Lion Corp 硫酸化キトサン誘導体及びその製造方法
EP0390481B1 (en) 1989-03-23 1996-02-28 Sanyo Chemical Industries Ltd. Surgical adhesive sheet
IT1229167B (it) 1989-04-10 1991-07-22 Texcontor Ets Complessi del ferro o di altri metalli con derivati solfonati del chitosano
US5071977A (en) 1989-05-10 1991-12-10 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Plaque inhibiting oligosaccharide
AU5885690A (en) 1989-07-11 1991-01-17 Union Carbide Chemicals And Plastics Company Inc. Emulsions comprising aminopolysaccharides
US5116747A (en) 1989-08-11 1992-05-26 University Of Waterloo Immobilization of biologically active material in capsules prepared from a water-soluble polymer and chitosan acetate
DK0426368T3 (da) 1989-10-31 1995-03-13 Howmedica Præparater indeholdende chitinderivater til forebyggelse af adhæsion
US5093319A (en) 1989-10-31 1992-03-03 Pfizer Hospital Products Group, Inc. Use of derivatives of chitin soluble in aqueous solutions for preventing adhesions
JPH064531B2 (ja) 1990-06-04 1994-01-19 アイセロ化学株式会社 大腸崩壊性硬質カプセル
US5463022A (en) 1990-08-17 1995-10-31 Drug Delivery System Institute, Ltd. N-acetylcarboxymethylchitosan derivatives and process for preparation thereof
ATE149545T1 (de) 1990-08-30 1997-03-15 Warner Lambert Co Formteile aus einer thermoplastischen stärkeschmelze
US5529914A (en) 1990-10-15 1996-06-25 The Board Of Regents The Univeristy Of Texas System Gels for encapsulation of biological materials
JPH04126701U (ja) 1991-05-13 1992-11-18 株式会社日立製作所 潤滑機能を有する下部軸受
US5382569A (en) 1991-05-16 1995-01-17 Warner-Lambert Company Endotherlin antagonists
JPH0691819B2 (ja) 1991-05-27 1994-11-16 工業技術院長 デアセチラーゼの製造方法
JP3046099B2 (ja) 1991-06-19 2000-05-29 ユニチカ株式会社 キチン又はキトサンの綿状物
CA2072395A1 (en) 1991-07-01 1993-01-02 John T. Hunt Bicyclic endothelin analogues
JPH0525289A (ja) 1991-07-19 1993-02-02 Unitika Ltd キチン成形体の製造法
JPH0532702A (ja) 1991-08-01 1993-02-09 Unitika Ltd 細胞接着性キチン
JPH0551465A (ja) 1991-08-23 1993-03-02 Unitika Ltd 球状キチンの製造方法
US5229123A (en) 1991-10-09 1993-07-20 Hoffmann-La Roche Inc. Antifungal agents
US5219749A (en) 1991-10-09 1993-06-15 Institute For Molecular Biology & Biotechnology/Forth Process for isolating and preparing purified chitin deacetylase
US5837747A (en) 1991-10-29 1998-11-17 Vivorx, Inc. Crosslinkable polysaccharides, polycations and lipids useful for encapsulation and drug release
AU669866B2 (en) 1991-11-05 1996-06-27 Smithkline Beecham Corporation Endothelin receptor antagonists
IL100096A (en) 1991-11-20 1996-03-31 Univ Ramot Method for entrapment of active materials in chitosan
US5260002A (en) 1991-12-23 1993-11-09 Vanderbilt University Method and apparatus for producing uniform polymeric spheres
DE4200080A1 (de) 1992-01-03 1993-09-30 Reinmueller Johannes Pharmazeutische Zusammensetzung zur Wund-, Narben- und Keloidbehandlung
JPH05235905A (ja) 1992-02-21 1993-09-10 Toshiba Corp Ｃｒｃ演算装置
JPH076126A (ja) 1992-02-26 1995-01-10 Nec Corp プロセッサ間バス伝送方式
US5573934A (en) 1992-04-20 1996-11-12 Board Of Regents, The University Of Texas System Gels for encapsulation of biological materials
JPH05271094A (ja) 1992-03-26 1993-10-19 Fuji Photo Film Co Ltd カルボキシメチル化キチン誘導体を用いる癌転移抑制剤
US5550110A (en) 1992-04-22 1996-08-27 Warner-Lambert Company Endothelin Antagonists II
WO1994003483A1 (en) 1992-07-30 1994-02-17 Chiron Corporation Endothelin receptor-binding compounds
US5871985A (en) 1992-09-28 1999-02-16 Brown University Research Foundation Particulate non cross-linked chitosan core matrices for encapsulated cells
TW394761B (en) 1993-06-28 2000-06-21 Hoffmann La Roche Novel Sulfonylamino Pyrimidines
US5447505A (en) 1993-08-04 1995-09-05 Merocel Corporation Wound treatment method
JPH07102458A (ja) 1993-09-30 1995-04-18 Unitika Ltd キチンウェブ状物
US5624679A (en) 1993-12-01 1997-04-29 Marine Polymer Technologies, Inc. Methods and compositions for poly-β-1-4-N-acetylglucosamine biological barriers
US5858350A (en) 1993-12-01 1999-01-12 Marine Polymer Technologies Methods and compositions for poly-β-1→4-N-acetylglucosamine cell therapy system
US5686115A (en) 1993-12-01 1997-11-11 Marine Polymer Technologies, Inc. Poly-β-1→4-N-acetylucosamine copolymer composition with collagen
US5846952A (en) 1993-12-01 1998-12-08 Marine Polymer Technologies, Inc. Methods and compositions for poly-β-1-4-N-acetylglucosamine drug delivery
US6743783B1 (en) 1993-12-01 2004-06-01 Marine Polymer Technologies, Inc. Pharmaceutical compositions comprising poly-β-1→4-N-acetylglucosamine
US5635493A (en) 1993-12-01 1997-06-03 Marine Polymer Technologies, Inc. Methods and compositions for poly-β-1-4-N-acetylglucosamine chemotherapeutics
US6063911A (en) 1993-12-01 2000-05-16 Marine Polymer Technologies, Inc. Methods and compositions for treatment of cell proliferative disorders
US5811416A (en) 1994-06-06 1998-09-22 Board Of Regents The University Of Texas System Endothelin antagonist and/or endothelin synthase inhibitor in combination with a progestin, an estrogen, a cyclooxygenase inhibitor, or a nitric acid donor or substrate
WO1996011927A1 (en) 1994-10-12 1996-04-25 Abbott Laboratories Endothelin antagonists
TW313568B (OSRAM) 1994-12-20 1997-08-21 Hoffmann La Roche
US5658943A (en) 1995-01-05 1997-08-19 Warner-Lambert Company Phenylalanine derivatives as endothelin antagonists
US5510102A (en) 1995-01-23 1996-04-23 The Regents Of The University Of California Plasma and polymer containing surgical hemostatic adhesives
WO1996039122A1 (en) 1995-06-06 1996-12-12 Marine Polymer Technologies, Inc. POLY-β-1→4-N-ACETYLGLUCOSAMINE
FR2736835B1 (fr) 1995-07-17 1997-10-10 Aber Technologies Pansement pour plaies chroniques, notamment escarres, en gel de chitine
AU6603996A (en) 1995-08-24 1997-03-19 Warner-Lambert Company Furanone endothelin antagonists
WO1997037987A1 (en) 1996-04-10 1997-10-16 Warner-Lambert Company Ketoacid endothelin antagonists
US5804594A (en) 1997-01-22 1998-09-08 Murad; Howard Pharmaceutical compositions and methods for improving wrinkles and other skin conditions
AU6187898A (en) 1997-01-30 1998-08-25 Bristol-Myers Squibb Company Method for preventing or treating low renin hypertension by administering an endothelin antagonist
US20030060434A1 (en) 1997-02-18 2003-03-27 Loretta Nielsen Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
US6162241A (en) 1997-08-06 2000-12-19 Focal, Inc. Hemostatic tissue sealants
EP0897914B1 (en) 1997-08-19 2004-05-26 F. Hoffmann-La Roche Ag Process for the preparation of 2,5-disubstitued pyridines
CA2234936C (en) 1998-04-17 2004-06-29 Glucogenics Pharmaceuticals Inc. Composition for and treatment of inflammatory bowel disease by colon administration of n-acetylglucosamine
US6046179A (en) 1998-04-17 2000-04-04 Murch; Simon Composition for and treatment of inflammatory bowel disease by colon administration of N-acetylglucosamine
DE19821598A1 (de) 1998-05-14 1999-11-18 Henkel Kgaa Verfahren zum Abbau von Biopolymeren
TW585762B (en) 1999-11-11 2004-05-01 Tanabe Seiyaku Co Pharmaceutical composition for prophylaxis or treatment of inflammatory bowel diseases
US7041657B2 (en) 2001-02-12 2006-05-09 Marine Polymer Technologies Inc. Compositions and methods for modulation of vascular structure and/or function
US8741335B2 (en) 2002-06-14 2014-06-03 Hemcon Medical Technologies, Inc. Hemostatic compositions, assemblies, systems, and methods employing particulate hemostatic agents formed from hydrophilic polymer foam such as Chitosan
US7371403B2 (en) 2002-06-14 2008-05-13 Providence Health System-Oregon Wound dressing and method for controlling severe, life-threatening bleeding
JP2003128704A (ja) 2001-10-24 2003-05-08 Matsumoto Shika Univ キチン・キトサンの低分子化方法及び骨伝導物の製造方法
GB0126923D0 (en) 2001-11-09 2002-01-02 Procter & Gamble Chitosan compositions
JP2005514352A (ja) 2001-11-14 2005-05-19 ラルフ ライバック 自己免疫疾患の治療法
US7037983B2 (en) 2002-06-14 2006-05-02 Kimberly-Clark Worldwide, Inc. Methods of making functional biodegradable polymers
US20090130186A1 (en) * 2002-06-14 2009-05-21 Hemcon Medical Technologies, Inc. Wound dressing assemblies, systems, and methods formed from hydrophilic polymer sponge structures such as chitosan and incorporating silver nanoparticles
AU2003263332A1 (en) 2002-09-11 2004-04-30 Johnson And Johnson Medical Limited Wound dressings for the treatment of wound infection
GB2393120A (en) 2002-09-18 2004-03-24 Johnson & Johnson Medical Ltd Compositions for wound treatment
US20070237812A1 (en) * 2006-04-11 2007-10-11 Tyco Healthcare Group Multi-layer wound dressings
JP2006515309A (ja) 2002-12-31 2006-05-25 マリン ポリマー テクノロジーズ，インコーポレーテッド 止血剤組成物およびその使用
WO2005027993A2 (en) 2003-09-12 2005-03-31 Marine Polymer Technologies, Inc. Vascular access preservation in hemodialysis patients
AU2004273738B2 (en) 2003-09-19 2011-02-03 Otsuka Pharmaceutical Co., Ltd. Human beta-defensin secretion promoter
RU2240830C1 (ru) 2003-12-26 2004-11-27 ФГУП Государственный научно-исследовательский институт особо чистых биопрепаратов Раневое покрытие и способ его получения
US7417037B2 (en) 2004-01-20 2008-08-26 The Board Of Regents Of The University Of Oklahoma Compositions and methods of treatment for inflammatory diseases
US7780873B2 (en) 2004-02-23 2010-08-24 Texas A&M University System Bioactive complexes compositions and methods of use thereof
JP2005281239A (ja) 2004-03-30 2005-10-13 Nippon Zeon Co Ltd 鶏用ｄｎａワクチン
US7704522B2 (en) 2004-09-08 2010-04-27 Clyde Morgan Topical medicament
CA2487564A1 (en) 2004-11-12 2006-05-12 Valorisation Recherche Hscm Folic acid-chitosan-dna nanoparticles
DE102004061406A1 (de) 2004-12-21 2006-07-06 Bayer Innovation Gmbh Infektionsresistente Polyurethanschäume, Verfahren zu ihrer Herstellung und Verwendung in antiseptisch ausgestatteten Wundauflagen
US20070036846A1 (en) * 2005-08-15 2007-02-15 Tsang Wing W M Wound dressing and method of manufacture thereof
EP1948810A4 (en) 2005-11-04 2010-06-30 Biosyntech Canada Inc COMPOSITION AND METHOD USING CHITOSAN FOR THE EFFICIENT ADMINISTRATION OF NUCLEIC ACIDS TO CELLS
US8277849B2 (en) 2006-01-19 2012-10-02 Solazyme, Inc. Microalgae-derived compositions for improving the health and appearance of skin
WO2007109812A2 (en) 2006-03-23 2007-09-27 Novartis Ag Immunopotentiating compounds
ATE539079T1 (de) 2006-03-23 2012-01-15 Novartis Ag Imidazochinoxalinverbindungen als immunmodulatoren
WO2008039390A2 (en) 2006-09-22 2008-04-03 Government Of The Usa., Dept. Of Health & Human Services Compositions and methods for chitosan enhanced immune response
US20120156137A1 (en) 2006-10-20 2012-06-21 Soo-Youl Kim Composition for treatment of atopic dermatitis comprising glucosamine and derivatives thereof and a method for treatment of atopic dermatitis using them
KR100882611B1 (ko) 2006-11-14 2009-02-12 주식회사 키토라이프 표적 리간드로서 폴릭산이 도입된 유전자 전달체용저분자량 수용성 키토산 나노입자 및 이의 제조방법
KR20090108723A (ko) 2007-01-31 2009-10-16 알러간, 인코포레이티드 안 약물 송달을 위한 신규한 생체적합물질 및 이의 제조방법 및 용도
US8436157B2 (en) 2008-03-26 2013-05-07 Tate & Lyle Technology Limited Method for the production of sucralose
KR20110031962A (ko) 2008-07-18 2011-03-29 노보자임스 아데니움 바이오테크 에이/에스 포유류 베타 방어소를 이용한 염증 질환의 치료
US20100086613A1 (en) 2008-10-03 2010-04-08 Chang-Jer Wu Chitosan vehicle and method for making same
US20100105139A1 (en) 2008-10-27 2010-04-29 Remco Alexander Spanjaard Ligand Targeted Nanocapsules for the delivery of RNAi and other Agents
CN107412772A (zh) 2010-04-15 2017-12-01 海洋聚合物技术公司 聚‑n‑乙酰葡萄糖胺纳米纤维的抗菌应用
CA2833415A1 (en) 2010-05-10 2011-11-17 Corporation De L'ecole Polytechnique De Montreal Gene therapy for diabetes with chitosan-delivered plasmid encoding glucagon-like peptide 1
MX358050B (es) 2010-11-06 2018-08-03 Marine Polymer Tech Inc Composiciones y métodos para la entrega de ácido nucleico a base de nanopolímeros.
CA2832859C (en) 2011-04-15 2020-06-16 Marine Polymer Technologies, Inc. Treatment of disease with poly-n-acetylglucosamine nanofibers
JP5496427B2 (ja) 2011-09-15 2014-05-21 国立大学法人鳥取大学 炎症性腸疾患治療剤
EP2968190B1 (en) 2013-03-14 2018-10-17 Marine Polymer Technologies, Inc. Treatment of disease with poly-n-acetylglucosamine nanofibers

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09506126A (ja) * 1993-12-01 1997-06-17 マリン ポリマー テクノロジーズ，インコーポレーテッド ポリ−β−１→４−Ｎ−アセチルグルコサミン
JP2003160602A (ja) * 2001-11-28 2003-06-03 Japan Atom Energy Res Inst 橋かけ構造を有するキチン誘導体及び／又はキトサン誘導体の製造方法
JP2008019264A (ja) * 2002-08-02 2008-01-31 Engelhard Lyon ２型又は３型ヒトβ−デフェンシンを刺激する活性成分とその活性成分を含有する化粧用組成物及び医薬組成物
JP2006518764A (ja) * 2003-02-24 2006-08-17 マリン ポリマー テクノロジーズ，インコーポレーテッド 細胞−ポリマー繊維組成物及びその使用
WO2008103345A2 (en) * 2007-02-19 2008-08-28 Marine Polymer Technologies, Inc. Hemostatic compositions and therapeutic regimens
WO2009095456A1 (en) * 2008-01-30 2009-08-06 Diverdrugs S.L. Peptide derivatives useful in the treatment, care or cleansing of the skin, mucosae, scalp or nails

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6015012899; Ｔｈｅ　Ｊｏｕｒｎａｌ　ｏｆ　Ｇｅｎｅ　Ｍｅｄｉｃｉｎｅ，　２００９，　Ｖｏｌ．１１，　ｐ．２２０-２２８ *
JPN7015000865; Ａｂｓｔｒａｃｔｓ　ｏｆ　ｐａｐｅｒｓ　Ａｍｅｒｉｃａｎ　Ｃｈｅｍｉｃａｌ　Ｓｏｃｉｅｔｙ，　２０１０／３，　ｐ．５２７-ＣＨＥＤ *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015048436A (ja) * 2013-09-03 2015-03-16 公立大学法人福井県立大学 植物の耐病性を向上させる、生物由来キチン質含有物、その使用方法、及びその製造方法

Also Published As

Publication number Publication date
US20180099003A1 (en) 2018-04-12
EP2563371A1 (en) 2013-03-06
MX342912B (es) 2016-10-19
US20190247410A1 (en) 2019-08-15
JP6761453B2 (ja) 2020-09-23
CN103108638A (zh) 2013-05-15
NZ703163A (en) 2016-06-24
EP2563371A4 (en) 2013-10-23
US9198928B2 (en) 2015-12-01
US10561677B2 (en) 2020-02-18
US9642871B2 (en) 2017-05-09
US10206938B2 (en) 2019-02-19
US20160235774A1 (en) 2016-08-18
HK1185278A1 (zh) 2014-02-14
US8858964B2 (en) 2014-10-14
CN107412772A (zh) 2017-12-01
US20130129789A1 (en) 2013-05-23
KR101883797B1 (ko) 2018-08-30
CA2796068A1 (en) 2011-10-20
CN103108638B (zh) 2016-11-09
CA2796068C (en) 2022-07-19
MX2012011816A (es) 2013-01-22
KR20130069625A (ko) 2013-06-26
IL222375A (en) 2017-07-31
JP6400628B2 (ja) 2018-10-03
AU2011239466A1 (en) 2012-11-01
US20150140045A1 (en) 2015-05-21
JP2018203766A (ja) 2018-12-27
AU2011239466B2 (en) 2015-01-22
NZ602909A (en) 2015-01-30
BR112012025844A2 (pt) 2017-07-18
WO2011130646A1 (en) 2011-10-20
IL222375A0 (en) 2012-12-31
JP2016196466A (ja) 2016-11-24

Similar Documents

Publication Publication Date Title
JP6761453B2 (ja) ポリ−ｎ−アセチルグルコサミンナノファイバーの抗菌性の適用
JP6328690B2 (ja) ポリ−ｎ−アセチルグルコサミンナノファイバを用いた疾患の治療
HK1185278B (en) Anti-bacterial applications of poly-n-acetylglucosamine nanofibers
AU2013205384B2 (en) Treatment of disease with poly-n-acetylglucosamine nanofibers
NZ616500B2 (en) Treatment of disease with poly-n-acetyglucosamine nanofibers

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140415

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140415

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150407

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150706

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151007

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160511

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20160511

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160511

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20160603

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160712

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161007

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170112

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20170120

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20170210